$21.30
1.38% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US87164F1057
Symbol
SNDX

Syndax Pharmaceuticals Inc Stock price

$21.30
+2.51 13.36% 1M
+12.30 136.67% 6M
+0.29 1.38% YTD
+7.22 51.28% 1Y
-4.15 16.31% 3Y
-1.04 4.66% 5Y
+9.29 77.35% 10Y
+9.29 77.35% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.29 1.38%
ISIN
US87164F1057
Symbol
SNDX
Industry

Key metrics

Basic
Market capitalization
$1.9b
Enterprise Value
$1.7b
Net debt
positive
Cash
$454.2m
Shares outstanding
86.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.6 | 10.9
EV/Sales
15.6 | 10.2
EV/FCF
negative
P/B
16.0
Financial Health
Equity Ratio
39.8%
Return on Equity
-110.6%
ROCE
-70.1%
ROIC
-
Debt/Equity
3.0
Financials (TTM | estimate)
Revenue
$111.6m | $170.5m
EBITDA
$-306.5m | $-268.3m
EBIT
$-306.5m | $-269.3m
Net Income
$-311.4m | $-276.7m
Free Cash Flow
$-310.6m
Growth (TTM | estimate)
Revenue
597.2% | 620.1%
EBITDA
4.6% | 21.0%
EBIT
4.6% | 20.7%
Net Income
-4.9% | 13.2%
Free Cash Flow
-19.8%
Margin (TTM | estimate)
Gross
95.4%
EBITDA
-274.8% | -157.4%
EBIT
-274.8%
Net
-279.2% | -162.2%
Free Cash Flow
-278.5%
More
EPS
$-3.6
FCF per Share
$-3.6
Short interest
29.6%
Employees
270
Rev per Employee
$90.0k
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

19x Buy
95%
1x Hold
5%

Analyst Opinions

20 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
95%
Hold
5%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
112 112
597% 597%
100%
- Direct Costs 5.09 5.09
-
5%
106 106
-
95%
- Selling and Administrative Expenses 168 168
59% 59%
150%
- Research and Development Expense 246 246
6% 6%
220%
-307 -307
5% 5%
-275%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -307 -307
5% 5%
-275%
Net Profit -311 -311
5% 5%
-279%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Positive
Seeking Alpha
17 days ago
Syndax Pharmaceuticals is now a commercial-stage biopharma with two FDA-approved drugs: Revuforj and Niktimvo. SNDX's Revuforj leads in efficacy for AML, with rapid market penetration and a first-mover advantage in front-line Phase 3 trials. Despite cardiac risk concerns, lower-dose combination data suggest manageable safety, supporting SNDX's strong buy rating.
Neutral
GlobeNewsWire
22 days ago
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best New Drug Award recognizes excellence in pharmaceutical development and the drug that represents the best thera...
Neutral
Seeking Alpha
26 days ago
Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 270
Founded 2005
Website syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today